Use of testosterone replacement therapy in patients with prostate cancer

被引：5
作者：
Dorff T.B. [1 ]
Vogelzang N.J. [2 ]
机构：
[1] USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA 90033
[2] US Oncology Research, C/o Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169
来源：
Current Urology Reports | 2011年 / 12卷 / 3期
关键词：
Hypogonadism; Prostate cancer; Testosterone;
D O I：
10.1007/s11934-011-0176-2
中图分类号：
学科分类号：
摘要：
Prostate cancer is among the more common and less lethal malignancies, yielding a large population of survivors. The incidence of hypogonadism increases in the same elderly population of men who most frequently develop prostate cancer, and the risk of becoming hypogonadal is increased further by prostate cancer therapy. The relative safety of replacing testosterone to reduce symptoms of hypogonadism in men who have been treated for prostate cancer is not well established. We review the available data, provide suggestions for approaching the management of prostate cancer survivors who suffer hypogonadal symptoms, and describe other diagnostic and therapeutic uses of testosterone that have been employed in patients with prostate cancer. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：223 / 228
页数：5
相关论文
共 40 条
  • [1] Kamangar F., Dores G.M., Anderson W.F., Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world, Journal of Clinical Oncology, 24, 14, pp. 2137-2150, (2006)
  • [2] Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R., Longitudinal effects of aging on serum total and free testosterone levels in healthy men, Journal of Clinical Endocrinology and Metabolism, 86, 2, pp. 724-731, (2001)
  • [3] Nejat R.J., Rashid H.H., Bagiella E., Et al., A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy, J Urol, 164, pp. 1891-4, (2000)
  • [4] Pickles T., Agranovich A., Berthelet E., Duncan G.G., Keyes M., Kwan W., McKenzie M.R., Morris W.J., Hoegler D., Kim-Sing C., Kostashuk E., Liu M., Po M., Tyldesley S., Wilson J., Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma, Cancer, 94, 2, pp. 362-367, (2002)
  • [5] Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., Kantoff P.W., Changes in body composition during androgen deprivation therapy for prostate cancer, Journal of Clinical Endocrinology and Metabolism, 87, 2, pp. 599-603, (2002)
  • [6] Keating N.L., O'Malley A.J., Smith M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, Journal of Clinical Oncology, 24, 27, pp. 4448-4456, (2006)
  • [7] Dhindsa S., Prabhakar S., Sethi M., Bandyopadhyay A., Chaudhuri A., Dandona P., Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes, Journal of Clinical Endocrinology and Metabolism, 89, 11, pp. 5462-5468, (2004)
  • [8] Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., Litwin M.S., Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer, Cancer, 110, 7, pp. 1493-1500, (2007)
  • [9] Bhasin S., Storer T.W., Berman N., Yarasheski K.E., Clevenger B., Phillips J., Lee W.P., Bunnell T.J., Casaburi R., Testosterone replacement increases fat-free mass and muscle size in hypogonadal men, Journal of Clinical Endocrinology and Metabolism, 82, 2, pp. 407-413, (1997)
  • [10] Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., Matsumoto A.M., Weber T., Berman N., Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men, Journal of Clinical Endocrinology and Metabolism, 85, 8, pp. 2839-2853, (2000)
1234